South Korean pharma, Boryung Corp., has announced a partnership with Taiwanese CDMO Lotus Pharmaceutical, for services focused on cytotoxic drugs and will take on the role of manufacturing an anticancer injection for Lotus.

The manufacturing process will be carried out at Boryung's state-of-the-art facility located in Yesan, South Chungcheong Province - a facility designed by Novo Nordisk Engineering (NNE), a renowned name in pharmaceutical plant design - with the partnership open to future collaborations in the oncology space.

The following article originally appeared in The Korea Economic Daily.

South Korea's Boryung Corp. said on Thursday it signed a contract with Lotus Pharmaceutical, a Taiwanese oncology firm, for contract development and manufacturing organization (CDMO) to cytotoxic drugs.

Under the agreement, Boryung will manufacture an anticancer injection for Lotus.

The company plans to supply the agent to Lotus starting in 2026.

The product name will be disclosed by agreement between the two companies.

Boryung will manufacture the anticancer drug at its EU-GMP-certified plant in Yesan, South Chungcheong Province.

The facility, designed by Novo Nordisk Engineering (NNE), can produce 6 million vials annually.

For more, please find the original story source here.